151. Stimulus-Responsive Microfluidic Interface Enables Efficient Enrichment and Cytogenetic Profiling of Circulating Myeloma Cells
- Author
-
Xiuqin Xu, Xiyuan Yu, Mingxia Zhang, Liu Yang, Chaoyong Yang, Zhi Zhu, Huimin Zhang, Rui Su, Yuanyuan Yang, Yilong Liu, Juan Song, and Shichao Lin
- Subjects
Materials science ,Stimuli responsive ,Microfluidics ,Cell Separation ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Cell Line, Tumor ,medicine ,Humans ,General Materials Science ,Multiple myeloma ,030304 developmental biology ,Chromosome Aberrations ,0303 health sciences ,biology ,Noninvasive sampling ,medicine.diagnostic_test ,Equipment Design ,Microfluidic Analytical Techniques ,medicine.disease ,Neoplastic Cells, Circulating ,Minimal residual disease ,Controlled release ,030220 oncology & carcinogenesis ,Cytogenetic Analysis ,Cancer research ,biology.protein ,Antibody ,Multiple Myeloma ,Fluorescence in situ hybridization - Abstract
Minimal residual disease (MRD) provides an independent prognostic factor for multiple myeloma (MM) patients. However, clinical MRD assays suffer from highly invasive sampling, insufficient detection sensitivity, and high cost. Herein, a stiMulus-Responsive ligand-Decorated microfluidic chip (MRD-Chip) was developed for efficient capture and controlled release of circulating myeloma cells (CMCs) in the peripheral blood for noninvasive myeloma evaluation. The CD138 antibody-decorated herringbone chip with a disulfide linker was designed to enhance the collision probability between blood cells and capture antibodies, leading to high capture efficiency of CMCs. More importantly, the captured CMCs can be nondestructively released via a thiol-exchange reaction, allowing them to be used for subsequent cellular and molecular analysis. By fluorescence in situ hybridization assay, we successfully identified the cytogenetic abnormalities (chromosome 1q21 amplification and p53 deletion) of CMCs in clinical samples. Overall, with the merits of noninvasive sampling, high capture efficiency (70.93%), high throughput (1.5 mL/h), and nondestructive release of target cells (over 90% viability) for downstream analysis, our strategy provides new opportunities for myeloma evaluation, such as prognosis assessment, efficacy monitoring, and mechanism research of disease relapse and drug resistance.
- Published
- 2021